Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Rising teen obesity prompts a surge in Novo Nordisk's Wegovy usage among adolescents, with prescriptions climbing 50% in 2024 ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

The data shows that the average rate of adolescents starting treatment with the Novo Nordisk (NYSE: NVO) drug increased by 50 ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England Journal of Medicine on May 11, the study attempted to analyze the comparative ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers, and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...

To her 34,000 social media followers, influencer Sophie Goodman appeared self-confident and happy – but that wasn’t the whole story ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

A report published in November by KFF, a health information nonprofit that includes KFF Health News, found only 13 states were covering GLP-1s for the treatment of obesity for Medicaid beneficiaries ...